January 2024
1. HE T, Zhang D
   Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.
   Gut. 2024 Jan 22:gutjnl-2023-331443. doi: 10.1136/gutjnl-2023-331443.
   

   >> Share

   
   
2. 
   Correction: Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
   Gut. 2024;73:e1.
   

   >> Share

   
   
3. LIN C, Luo L, Xun Z, Zhu C, et al
   Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection.
   Gut. 2024;73:338-349.
   

   >> Share

   
   November 2023
4. WANG Y, Li Q, Li C, Wang C, et al
   Chimeric antigen receptors of HBV envelope proteins inhibit hepatitis B surface antigen secretion.
   Gut. 2023 Nov 16:gutjnl-2023-330537. doi: 10.1136/gutjnl-2023-330537.
   

   >> Share

   
   
5. YU X, Gong Q, Yu D, Chen Y, et al
   Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss.
   Gut. 2023 Nov 15:gutjnl-2023-330577. doi: 10.1136/gutjnl-2023-330577.
   

   >> Share

   
   October 2023
6. TESTONI B, Scholtes C, Plissonnier ML, Paturel A, et al
   Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
   Gut. 2023 Oct 25:gutjnl-2023-330644. doi: 10.1136/gutjnl-2023-330644.
   

   >> Share

   
   
7. CHOI WM, Kim GA, Choi J, Choi GH, et al
   Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
   Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
   

   >> Share

   
   
8. LIU Z, Lin C, Mao X, Guo C, et al
   Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people.
   Gut. 2023 Oct 5:gutjnl-2023-330691. doi: 10.1136/gutjnl-2023-330691.
   

   >> Share

   
   September 2023
9. LE BERT N, Fisicaro P
   Enolase: a metabolic checkpoint behind diverse exhaustion stages of CD8+ T cells in chronic HBV and HCV.
   Gut. 2023 Sep 6:gutjnl-2023-330541. doi: 10.1136/gutjnl-2023-330541.
   

   >> Share

   
   August 2023
10. WINKLER F, Hipp AV, Ramirez C, Martin B, et al
    Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8(+) T cells.
    Gut. 2023 Aug 4:gutjnl-2022-328734. doi: 10.1136/gutjnl-2022-328734.
    

    >> Share

    
    
11. MENG CY, Sun S, Liang Y, Xu H, et al
    Engineered anti-PDL1 with IFNalpha targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.
    Gut. 2023;72:1544-1554.
    

    >> Share

    
    March 2023
12. GIRALDEZ-GALLEGO A, Rodriguez-Seguel EDP, Valencia-Martin R, Morillo-Garcia A, et al
    Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
    Gut. 2023 Mar 24:gutjnl-2022-328222. doi: 10.1136/gutjnl-2022-328222.
    

    >> Share

    
    January 2023
13. ROSSI M, Vecchi A, Tiezzi C, Barili V, et al
    Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro.
    Gut. 2023 Jan 30:gutjnl-2022-327202. doi: 10.1136/gutjnl-2022-327202.
    

    >> Share

    
    
14. ALLWEISS L, Testoni B, Yu M, Lucifora J, et al
    Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure.
    Gut. 2023 Jan 27:gutjnl-2022-328380. doi: 10.1136/gutjnl-2022-328380.
    

    >> Share

    
    
15. TESTONI B, Ploss A
    Cracking the host functional network involved in hepatitis B virus cccDNA biology.
    Gut. 2023 Jan 27:gutjnl-2022-329185. doi: 10.1136/gutjnl-2022-329185.
    

    >> Share

    
    
16. JANSSEN HLA, Hou J, Asselah T, Chan HLY, et al
    Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
    Gut. 2023 Jan 25:gutjnl-2022-328041. doi: 10.1136/gutjnl-2022-328041.
    

    >> Share

    
    
17. HENDRIKX T, Lang S, Rajcic D, Wang Y, et al
    Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice.
    Gut. 2023 Jan 23:gutjnl-2022-328265. doi: 10.1136/gutjnl-2022-328265.
    

    >> Share

    
    
18. EFFENBERGER M, Widjaja AA, Grabherr F, Schaefer B, et al
    Interleukin-11 drives human and mouse alcohol-related liver disease.
    Gut. 2023;72:168-179.
    

    >> Share

    
    October 2022
19. LANG-MELI J, Neumann-Haefelin C
    Prophylactic vaccination against hepatitis D virus superinfection: from fiction to reality?
    Gut. 2022 Oct 19. pii: gutjnl-2022-328381. doi: 10.1136/gutjnl-2022-328381.
    

    >> Share

    
    September 2022
20. VENTURA-COTS M, Argemi J, Jones PD, Lackner C, et al
    Clinical, histological and molecular profiling of different stages of alcohol-related liver disease.
    Gut. 2022;71:1856-1866.
    

    >> Share

    
    August 2022
21. BURM R, Maravelia P, Ahlen G, Ciesek S, et al
    Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.
    Gut. 2022 Aug 17. pii: gutjnl-2022-327216. doi: 10.1136/gutjnl-2022-327216.
    

    >> Share

    
    
22. ALZUA GP, Pihl AF, Offersgaard A, Duarte Hernandez CR, et al
    Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice.
    Gut. 2022 Aug 2. pii: gutjnl-2021-326323. doi: 10.1136/gutjnl-2021-326323.
    

    >> Share

    
    
23. LAUER GM
    Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.
    Gut. 2022 Aug 1. pii: gutjnl-2022-327761. doi: 10.1136/gutjnl-2022-327761.
    

    >> Share

    
    July 2022
24. WIGGINS BG, Pallett LJ, Li X, Davies SP, et al
    The human liver microenvironment shapes the homing and function of CD4(+) T-cell populations.
    Gut. 2022;71:1399-1411.
    

    >> Share

    
    May 2022
25. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
    Defining the key intrahepatic gene networks in HCV infection driven by sex.
    Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
    

    >> Share

    
    
26. GORGULU E, Gu W, Trebicka J, Mucke VT, et al
    Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?
    Gut. 2022;71:1036-1038.
    

    >> Share

    
    February 2022
27. ALLWEISS L, Giersch K, Pirosu A, Volz T, et al
    Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.
    Gut. 2022;71:372-381.
    

    >> Share

    
    January 2022
28. LI J, Liang X, Jiang J, Yang L, et al
    PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.
    Gut. 2022;71:163-175.
    

    >> Share

    
    October 2021
29. ALIABADI E, Urbanek-Quaing M, Maasoumy B, Bremer B, et al
    Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection.
    Gut. 2021 Oct 26. pii: gutjnl-2021-324646. doi: 10.1136/gutjnl-2021-324646.
    

    >> Share

    
    
30. HSU YC, Tseng CH, Su TH, Kao JH, et al
    Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities.
    Gut. 2021 Oct 20. pii: gutjnl-2021-326232. doi: 10.1136/gutjnl-2021-326232.
    

    >> Share

    
    
31. TRIVEDI PJ, Hirschfield GM
    Recent advances in clinical practice: epidemiology of autoimmune liver diseases.
    Gut. 2021;70:1989-2003.
    

    >> Share

    
    September 2021
32. HALL SAL, Vogrin S, Wawryk O, Burns GS, et al
    Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
    Gut. 2021 Sep 7. pii: gutjnl-2020-323979. doi: 10.1136/gutjnl-2020-323979.
    

    >> Share

    
    June 2021
33. URBAN S, Neumann-Haefelin C, Lampertico P
    Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.
    Gut. 2021 Jun 8. pii: gutjnl-2020-323888. doi: 10.1136/gutjnl-2020-323888.
    

    >> Share

    
    May 2021
34. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    

    >> Share

    
    
35. JINDAL A, Vyas A, Dubey G
    Ponder of concern and long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil.
    Gut. 2021 May 5. pii: gutjnl-2021-324967. doi: 10.1136/gutjnl-2021-324967.
    

    >> Share

    
    April 2021
36. PHAM LV, Pedersen MS, Fahnoe U, Fernandez-Antunez C, et al
    HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Gut. 2021 Apr 8. pii: gutjnl-2020-323585. doi: 10.1136/gutjnl-2020-323585.
    

    >> Share

    
    March 2021
37. HERNAEZ R, Thimme R
    End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.
    Gut. 2021 Mar 30. pii: gutjnl-2021-324288. doi: 10.1136/gutjnl-2021-324288.
    

    >> Share

    
    
38. LI J, Li J, Chen S, Yuan Q, et al
    Naturally occurring 5' preS1 deletions markedly enhance replication and infectivity of HBV genotype B and genotype C.
    Gut. 2021;70:575-584.
    

    >> Share

    
    February 2021
39. WIJAYA RS, Read SA, Truong NR, Han S, et al
    HBV vaccination and HBV infection induces HBV-specific natural killer cell memory.
    Gut. 2021;70:357-369.
    

    >> Share

    
    December 2020
40. KIM MA, Kim SU, Sinn DH, Jang JW, et al
    Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Gut. 2020;69:2214-2222.
    

    >> Share

    
    October 2020
41. CASTRY M, Cousien A, Supervie V, Velter A, et al
    Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
    Gut. 2020 Oct 27. pii: gutjnl-2020-321744. doi: 10.1136/gutjnl-2020-321744.
    

    >> Share

    
    September 2020
42. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    

    >> Share

    
    March 2020
43. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share